VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. The results also showed that both BiTAC-ADC components were required to produce the intended tumor-specific response.
Additional in vitro studies demonstrated the platform's ability to distinguish cancer cells from healthy cells, prevent the release of active toxins outside the tumor and target multiple cancer cell lines. The findings support the potential of BiTAC-ADCs to deliver efficacy comparable to conventional antibody-drug conjugates while offering a differentiated safety profile designed to reduce systemic toxicity.
The announcement matters because it marks the first in vivo validation of the BiTAC-ADC platform, moving it from concept to demonstrated efficacy in a living organism. This is a critical milestone for any oncology therapeutic, as in vivo data is a prerequisite for advancing toward clinical trials. The ability to achieve tumor regression with a single low dose, without weight loss, suggests a favorable therapeutic index that could translate into better tolerability for patients. If the platform's differentiated safety profile holds up in further studies, BiTAC-ADCs could address a major limitation of conventional ADCs: off-target toxicity that often limits dosing and patient eligibility.
Moreover, the requirement for both components to produce the tumor-specific response indicates a built-in specificity mechanism that could reduce damage to healthy tissues. The platform's capacity to target multiple cancer cell lines hints at broad applicability across cancer types, potentially expanding the market for VERAXA's pipeline. As the company advances its ADC and proprietary BiTAC formats into clinical development, these data could attract partnership interest or accelerate internal programs.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats.
For investors, the presentation at the World ADC Congress provides independent validation of VERAXA's technology and could serve as a catalyst for the stock. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA. To view the full press release, visit https://ibn.fm/cs8SW. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially. Undue reliance should not be placed on such statements when making an investment decision.
